Search

Your search keyword '"Faust G"' showing total 235 results
Start Over Author "Faust G"
235 results on '"Faust G"'

1. 1772P Characterisation of a DNA repair deficiency (DRD) biomarker phenotype in metastatic urothelial carcinoma (mUC) within the ATLANTIS clinical trial platform

Author

Crabb, S.J., primary, Dempsey, L., additional, Soulis, E., additional, Hinsley, S., additional, Song, Y.P., additional, Barber, J., additional, Frew, J., additional, Gale, J., additional, Faust, G., additional, Brock, S., additional, McGovern, U.B., additional, Parikh, O.A., additional, Enting, D., additional, Sundar, S., additional, Ratnayake, G., additional, Lees, K., additional, Hussain, S.A., additional, Powles, T.B., additional, Jones, R., additional, and Tapper, W., additional

Published
2022
Full Text
View/download PDF

3. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (vol 29, pg 1843, 2018)

Author

Corrie, PG, Marshall, A, Nathan, PD, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, CG, Marples, M, Danson, SJ, Marshall, E, Houston, SJ, Board, RE, Waterston, AM, Nobes, JP, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, PM, Ottensmeier, CH, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, EO, Harman, C, Weiss, M, Myers, KA, Chhabra, A, Rodwell, SH, Dunn, JA, Middleton, MR, and Investigators, AVAST-M

Published
2019

4. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Author

Corrie, PG, Marshall, A, Nathan, PD, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, CG, Marples, M, Danson, SJ, Marshall, E, Houston, SJ, Board, RE, Waterston, AM, Nobes, JP, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, PM, Ottensmeier, CH, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, EO, Harman, C, Weiss, M, Myers, KA, Chhabra, A, Rodwell, SH, Dunn, JA, Middleton, MR, AVAST-M Investigators, Nathan, P, Dziewulski, P, Holikova, S, Panwar, U, Thomas, A, Corrie, P, Sirohi, B, Kelly, C, Middleton, M, Danson, S, Lester, J, Ajaz, M, Houston, S, Board, R, Eaton, D, Waterston, A, Nobes, J, Loo, S, Gray, G, Stubbings, H, Marsden, J, Patel, P, Ottensmeier, C, Dega, R, Herbert, C, Price, C, Brunt, M, Scott-Brown, M, Hamilton, J, Hayward, RL, Smyth, J, Woodings, P, Nayak, N, Burrows, L, Wolstenholme, V, Wagstaff, J, Nicolson, M, Wilson, A, Barlow, C, Scrase, C, Podd, T, Gonzalez, M, Stewart, J, Highley, M, Grumett, S, Talbot, T, Nathan, K, Coltart, R, and Gee, B

Subjects
Oncology, 0301 basic medicine, Male, Skin Neoplasms, Time Factors, medicine.medical_treatment, Dermatologic Surgical Procedures, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Clinical endpoint, Melanoma, Aged, 80 and over, Manchester Cancer Research Centre, Hazard ratio, adjuvant therapy, Hematology, Middle Aged, Corrigenda, Vascular endothelial growth factor, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Adjuvant, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Bevacizumab, Adolescent, bevacizumab, Disease-Free Survival, Drug Administration Schedule, RC0254, 03 medical and health sciences, Young Adult, Internal medicine, medicine, Adjuvant therapy, melanoma, Humans, Watchful Waiting, Survival analysis, Aged, Neoplasm Staging, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Original Articles, medicine.disease, Survival Analysis, Confidence interval, 030104 developmental biology, chemistry, Mutation, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

Background Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence. Patients and methods Patients with resected AJCC stage IIB, IIC and III cutaneous melanoma were randomised to receive either adjuvant bevacizumab (7.5 mg/kg i.v. 3 weekly for 1 year) or standard observation. The primary end point was detection of an 8% difference in 5-year overall survival (OS) rate; secondary end points included disease-free interval (DFI) and distant metastasis-free interval (DMFI). Tumour and blood were analysed for prognostic and predictive markers. Results Patients (n=1343) recruited between 2007 and 2012 were predominantly stage III (73%), with median age 56 years (range 18–88 years). With 6.4-year median follow-up, 515 (38%) patients had died [254 (38%) bevacizumab; 261 (39%) observation]; 707 (53%) patients had disease recurrence [336 (50%) bevacizumab, 371 (55%) observation]. OS at 5 years was 64% for both groups [hazard ratio (HR) 0.98; 95% confidence interval (CI) 0.82–1.16, P = 0.78). At 5 years, 51% were disease free on bevacizumab versus 45% on observation (HR 0.85; 95% CI 0.74–0.99, P = 0.03), 58% were distant metastasis free on bevacizumab versus 54% on observation (HR 0.91; 95% CI 0.78–1.07, P = 0.25). Forty four percent of 682 melanomas assessed had a BRAFV600 mutation. In the observation arm, BRAF mutant patients had a trend towards poorer OS compared with BRAF wild-type patients (P = 0.06). BRAF mutation positivity trended towards better OS with bevacizumab (P = 0.21). Conclusions Adjuvant bevacizumab after resection of high-risk melanoma improves DFI, but not OS. BRAF mutation status may predict for poorer OS untreated and potential benefit from bevacizumab. Clinical Trial Information ISRCTN 81261306; EudraCT Number: 2006-005505-64

Published
2018

7. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

Author

Corrie, P.G., primary, Marshall, A., additional, Nathan, P.D., additional, Lorigan, P., additional, Gore, M., additional, Tahir, S., additional, Faust, G., additional, Kelly, C.G., additional, Marples, M., additional, Danson, S.J., additional, Marshall, E., additional, Houston, S.J., additional, Board, R.E., additional, Waterston, A.M., additional, Nobes, J.P., additional, Harries, M., additional, Kumar, S., additional, Goodman, A., additional, Dalgleish, A., additional, Martin-Clavijo, A., additional, Westwell, S., additional, Casasola, R., additional, Chao, D., additional, Maraveyas, A., additional, Patel, P.M., additional, Ottensmeier, C.H., additional, Farrugia, D., additional, Humphreys, A., additional, Eccles, B., additional, Young, G., additional, Barker, E.O., additional, Harman, C., additional, Weiss, M., additional, Myers, K.A., additional, Chhabra, A., additional, Rodwell, S.H., additional, Dunn, J.A., additional, and Middleton, M.R., additional

Published
2019
Full Text
View/download PDF

14. Der Stellenwert von Organspende / Organspendeausweis in rheinlandpfälzischen Hausarztpraxen – eine Fragebogenstudie

Author

Brantzen, KB, Kirch, P, Faust, G, and Jansky, M

Subjects
finanzielle Anreize für Organspender, ddc: 610, Entscheidungslösung, 610 Medical sciences, Medicine, Widerspruchslösung, Stellenwert von Organspende / Organspendeausweis bei Hausärzten in RLP, Patientenseitige Gründe gegen Entscheidung zur Organspende
Abstract

Hintergrund: In vielen Musterformularen zur Patientenverfügung (PV) wird auch die Organspendebereitschaft abgefragt. Im Rahmen einer PV-Befragungsstudie wurde dieses Thema ergänzend angesprochen. Fragestellung: Stellenwert des Organspendeausweises in rheinland-pfälzischen Hausarztpraxen[zum vollständigen Text gelangen Sie über die oben angegebene URL], 51. Kongress für Allgemeinmedizin und Familienmedizin

Published
2017
Full Text
View/download PDF

15. Der Stellenwert der Patientenverfügung in rheinlandpfälzischen Hausarztpraxen – eine Fragebogenstudie

Author

Brantzen, KB, Kirch, P, Faust, G, and Jansky, M

Subjects
Hinderungsgründe gegen die Abfassung einer PV, ddc: 610, Patientenautonomie, Stellenwert der Patientenverfügung (PV) bei rheinlandpfälzischen Hausärzten, Zunahme schwieriger Entscheidungssituationen in Geriatrie und Palliativmedizin, 610 Medical sciences, Medicine
Abstract

Hintergrund: Die Zahl älterer Patienten wird künftig weiter steigen, parallel dazu wird medizinisch immer mehr „machbar“. Schwierige geriatrische / palliativmedizinische Entscheidungssituationen werden zunehmen, das Thema Patientenverfügung (PV) dürfte weiter an[zum vollständigen Text gelangen Sie über die oben angegebene URL], 51. Kongress für Allgemeinmedizin und Familienmedizin

Published
2017
Full Text
View/download PDF

18. VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium (TCCU): a retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through free of charge programme (FOCP) for patients in the UK and Ireland

Author

Hussain, S., primary, Ansari, J., additional, Huddart, R., additional, Power, D., additional, Lyons, J., additional, Wylie, J., additional, Vilarino-Varela, M., additional, Elander, N., additional, McMenemin, R., additional, Pickering, L., additional, Faust, G., additional, Chauhan, S., additional, and Jakson, R., additional

Published
2016
Full Text
View/download PDF

24. 2632 VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium (TCCU): A retrospective analysis of the use of Vinflunine in a multi-centre real life setting as second line chemotherapy through the free of charge programme (FOCP) for patients in the UK

Author

Hussain, S., primary, Jackson, R., additional, Chauhan, S., additional, Ansari, J., additional, Huddart, R., additional, Harrold, E., additional, Power, D., additional, Lyons, J., additional, Wylie, J., additional, Vilarino-Varela, M., additional, Wilkinson, D., additional, McMenemin, R., additional, Pickering, L., additional, and Faust, G., additional

Published
2015
Full Text
View/download PDF

25. Finite Element-Analyse vier verschiedener Implante zur Stabilisierung einer idealisierten pertrochantären Femurfraktur in zwei verschiedenen Positionen

Author

Helwig, P, Faust, G, Ulrich, U, Südkamp, NP, and Schneider, R

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Fragestellung: Biomechanische Analysen der idealen Platzierung der neueren intramedullären Implantate zur Stabilisierung von pertrochantären Femurfrakturen ist derzeit nicht verfügbar. Das Ziel der hier vorliegenden Studie, ist es festzustellen inwieweit sich vier verschiedene intramedulläre[for full text, please go to the a.m. URL], Deutscher Kongress für Orthopädie und Unfallchirurgie; 73. Jahrestagung der Deutschen Gesellschaft für Unfallchirurgie, 95. Tagung der Deutschen Gesellschaft für Orthopädie und Orthopädische Chirurgie, 50. Tagung des Berufsverbandes der Fachärzte für Orthopädie

Published
2009
Full Text
View/download PDF

27. 800P - VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium (TCCU): a retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through free of charge programme (FOCP) for patients in the UK and Ireland

Author

Hussain, S., Ansari, J., Huddart, R., Power, D., Lyons, J., Wylie, J., Vilarino-Varela, M., Elander, N., McMenemin, R., Pickering, L., Faust, G., Chauhan, S., and Jakson, R.

Published
2016
Full Text
View/download PDF

32. Nacelle design

Author

Faust, G. K and Mungur, Parma

Subjects
Aircraft Design, Testing And Performance
Abstract

The external cowlings of engine nacelles on large turbofan powered aircraft are good candidates for application of natural laminar flow. These nacelles usually have shorter characteristic lengths than other candidate surfaces such as wings and fuselages and therefore have lower characteristic Reynolds numbers. A conceptive figure of the natural flow nacelle (NLF) is shown. On the typical nacelle the flow accelerates to a curvature induced velocity peak near the lip and then decelerates over the remainder of the nacelle length. Transition occurs near the start of the deceleration, so turbulent flow with high friction coefficient exists over most of the nacelle length. On the other hand, the NLF nacelle is contoured to have an accelerating flow over most of its length, so transition is delayed, and a relatively lower friction drag exists over most of the nacelle. The motivation for development of the LFN is a potential 40 to 50 percent reduction in nacelle friction drag.

Published
1987

33. Status report on a natural laminar-flow nacelle flight experiment

Author

Hastings, Earl C., Jr, Faust, G. K, Mungur, Parma, Obara, Clifford J, Dodbele, S. S, Schoenster, James A, and Jones, Michael G

Subjects
Aircraft Design, Testing And Performance
Abstract

The natural laminar flow (NLF) nacelle experiment is part of a drag reduction production program, and has the dual objectives of studying the extent of NLF on full scale nacelles in a flight environment and the effect of acoustic disturbance on the location of transition on the nacelle surface. The experiment is being conducted in two phases: (1) an NLF fairing was flown on a full scale Citation nacelle to develop the experiment technique and establish feasibility; (2) full scale, flow through, NLF nacelles located below the right wing of an experimental NASA OV-1 aircraft are evaluated. The measurements of most interest are the static pressure distribution and transition location on the nacelle surface, and the fluctuating pressure levels associated with the noise sources. Data are collected in combinations of acoustic frequencies and sound pressure levels. The results of phase 2 tests to date indicate that on shape GE2, natural laminar flow was maintained as far aft as the afterbody joint at 50 percent of the nacelle length. An aft facing step at this joint caused premature transition at this station. No change was observed in the transition pattern when the noise sources were operated.

Published
1987

Catalog

Books, media, physical & digital resources
See catalog results